Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06453044 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

StatusRecruiting
PhasePhase 2
Started2024-09-09
View on ClinicalTrials.gov ↗

Amendment history

2025-09-19
Study Identification, Study Status, Contacts/Locations v3
Study sitescontacts updated at 2 of 2 sites
Study titlerevised
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients withWith Relapsed or Refractory Grade 1-3a Follicular Lymphoma
2024-09-17
Study Identification, Study Status, Contacts/Locations v2
Start dateestimated 2024-08-24→confirmed 2024-09-09
Study sites1→2
Study titlerevised
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients Withwith Relapsed or Refractory Grade 1-3a Follicular Lymphoma
2024-08-14
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-03-18→2028-03-14
Completion date2027-03-18→2028-03-14
Study sitesdetails revised at 1 of 1 site
2024-06-06
Original filing
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Giving mosunetuzumab and polatuzumab vedotin may kill more cancer cells in patients with relapsed or refractory grade 1-3a follicular lymphoma.
Trial Details
NCT Number NCT06453044
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Enrollment 41 participants
Start Date 2024-09-09
Primary Completion 2028-03-14 (estimated)
Study Completion 2028-03-14 (estimated)
Updated on ClinicalTrials.gov 2026-09-22